An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline: Surveillance Strategies in Patients with Stage I, II, III or Resectable IV Melanoma Who Were Treated with Curative Intent.

Clinical practice guideline follow-up frequency imaging melanoma surveillance

Journal

Clinical oncology (Royal College of Radiologists (Great Britain))
ISSN: 1433-2981
Titre abrégé: Clin Oncol (R Coll Radiol)
Pays: England
ID NLM: 9002902

Informations de publication

Date de publication:
20 Jan 2024
Historique:
received: 06 10 2023
revised: 20 12 2023
accepted: 15 01 2024
medline: 10 2 2024
pubmed: 10 2 2024
entrez: 9 2 2024
Statut: aheadofprint

Résumé

To make recommendations on managing the surveillance of patients with stage I, II, III or resectable IV melanoma who are clinically free of disease following treatment with curative intent. This guideline was developed by Ontario Health's (Cancer Care Ontario's) Program in Evidence-Based Care and the Melanoma Disease Site Group (including seven medical oncologists, four surgical oncologists, three dermatologists, one radiation oncologist and one patient representative). The MEDLINE, EMBASE, Cochrane Library, PROSPERO databases and the main relevant guideline websites were searched. Internal and external reviews were conducted, with final approval by the Program in Evidence-Based Care and the Melanoma Disease Site Group. The Grading of Recommendations, Assessment, Development and Evaluation approach was followed, and the Modified Delphi method was used. Based on the current evidence (eight eligible original study papers and four relevant guidelines) and the clinical opinions of the authors of this guideline, the initial recommendations were made. To reach 75% agreement for each recommendation, the Melanoma Disease Site Group (16 members) voted twice and one recommendation was voted on three times. After a comprehensive internal and external review process (including national and international reviewers), 12 recommendations, three weak recommendations and six qualified statements were ultimately made. After a systematic review, a comprehensive internal and external review process and a consensus process, the current guideline has been created. The guideline authors believe that this guideline will help clinicians, patients and policymakers make well-informed healthcare decisions that will guide them in clinical melanoma surveillance and ultimately assist in improving patient outcomes.

Identifiants

pubmed: 38336503
pii: S0936-6555(24)00028-1
doi: 10.1016/j.clon.2024.01.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Auteurs

S Rajagopal (S)

Trillium Health Partners, Credit Valley Hospital, Peel Regional Cancer Centre, Mississauga, Ontario, Canada. Electronic address: Sudha.rajagopal@thp.ca.

X Yao (X)

Department of Oncology, Department of Health Research Methods Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; Program in Evidence-Based Care, Ontario Health (Cancer Care Ontario), Hamilton, Ontario, Canada. Electronic address: yaoxia@mcmaster.ca.

W Abadir (W)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Ontario, Canada.

T D Baetz (TD)

Cancer Centre of Southeastern Ontario, Queen's Cancer Research Institute, Kingston, Ontario, Canada.

A M Easson (AM)

Department of Surgery, Marvelle Koffler Breast Centre, Mount Sinai Hospital, Toronto, Ontario, Canada.

G Knight (G)

Department of Oncology, Grand River Regional Cancer Centre, Grand River Hospital, Kitchener, Ontario, Canada.

E McWhirter (E)

Department of Medical Oncology, Juravinski Cancer Centre, Hamilton Health Sciences, Hamilton, Ontario, Canada.

C Nessim (C)

Department of Surgery, University of Ottawa, The Ottawa Hospital, Ottawa, Ontario, Canada.

C F Rosen (CF)

Division of Dermatology, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada.

A Sun (A)

Department of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.

F C Wright (FC)

Department of Surgery, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.

T M Petrella (TM)

Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Electronic address: Teresa.petrella@sunnybrook.ca.

Classifications MeSH